Health Care Innovation
Biosimilars
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
Commentary
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
Commentary
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Commentary
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
Blog
Learn about case that could threaten medical innovation
PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California
In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
Commentary
Learn more about California's doctor shortage
California needs more than medical schools to solve doctor shortage
California doesn’t have enough doctors. This year, the state met just 54% of its primary care needs. It would take 881 more physicians to eliminate all the state’s designated primary care shortage areas, where more than 5.8 million Californians currently reside. California’s leaders are trying to conjure up more physicians. ...
Commentary
Learn more about how Harris' plan might promote healthcare fraud
Will Harris’ Promises of New Era for Healthcare Invite Fraud?
For a former prosecutor and Calif. Atty. Gen. Kamala Harris sure seems to have a laissez-faire attitude toward fraud. In the race to enroll as many Americans as possible in Medicaid and in Obamacare exchange plans, the Biden-Harris administration has looked the other way as millions of Americans receive publicly ...
Commentary
Learn more about how competition can lower premiums
Competition Is The Cure For Rising Health Insurance Premiums
The presidential election is just a week away. And the rising prices of many products and services are on voters’ minds. Just over 40% of Americans say inflation is their biggest concern heading into November, according to a recent survey. In few markets are rising prices more apparent than in ...
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
RFK Jr.’s Confirmation Hearings Can’t Leave This Question Unanswered
On this Wednesday and Thursday, two powerful Senate committees will hold confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the Department of Health and Human Services. RFK Jr. is no stranger to controversy. But his most radical policy position may be one that relatively few people ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
Learn about case that could threaten medical innovation
PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California
In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
Learn more about California's doctor shortage
California needs more than medical schools to solve doctor shortage
California doesn’t have enough doctors. This year, the state met just 54% of its primary care needs. It would take 881 more physicians to eliminate all the state’s designated primary care shortage areas, where more than 5.8 million Californians currently reside. California’s leaders are trying to conjure up more physicians. ...
Learn more about how Harris' plan might promote healthcare fraud
Will Harris’ Promises of New Era for Healthcare Invite Fraud?
For a former prosecutor and Calif. Atty. Gen. Kamala Harris sure seems to have a laissez-faire attitude toward fraud. In the race to enroll as many Americans as possible in Medicaid and in Obamacare exchange plans, the Biden-Harris administration has looked the other way as millions of Americans receive publicly ...
Learn more about how competition can lower premiums
Competition Is The Cure For Rising Health Insurance Premiums
The presidential election is just a week away. And the rising prices of many products and services are on voters’ minds. Just over 40% of Americans say inflation is their biggest concern heading into November, according to a recent survey. In few markets are rising prices more apparent than in ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
